Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06386445

Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT: Cohort Study

Study on the Serum Metabolic Markers and Early Complications After Allogeneic Hematopoietic Stem Cell Transplantation in Hemaotological Diseases: Cohort Study

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
500 (estimated)
Sponsor
First Affiliated Hospital Xi'an Jiaotong University · Academic / Other
Sex
All
Age
0 Years – 65 Years
Healthy volunteers

Summary

This study aims to establish a cohort of 500 patients with hematological disease who undergoing allogeneic hematopoietic stem cell transplantation in the northwest region. All patients will be followed up at the outpatient clinic once a week after transplantation until 100 days after transplantation to observe the presence of acute graft versus host disease, acute kidney damage, and major cardiovascular adverse events. Serum samples from the day before pre-treatment, day after pre-treatment, 2 weeks,4 weeks,8 weeks and 12 weeks after transplantation will be detected by metabolomics sequencing.The primary objective is to explore the serum metabolic markers of acute graft versus host disease,acute kidney injury, and major adverse cardiac events within 100 days after transplantation,the secondary objective is to observe the high-risk factors for early complications.

Detailed description

This study aims to establish a cohort of 500 patients with hematological disease who undergoing allogeneic hematopoietic stem cell transplantation in the northwest region. All patients will be followed up at the outpatient clinic once a week after transplantation until 100 days after transplantation to observe the presence of acute graft versus host disease, acute kidney damage, and major cardiovascular adverse events. Baseline characterisitcs of patients, including gender, age, disease type, transplant type, donor gender and age, pre-transplant baseline electrocardiogram, myocardial enzymology, renal function, and other indicators were recorded. Serum samples from the day before pre-treatment, day after pre-treatment, 2 weeks,4 weeks,8 weeks and 12 weeks after transplantation will be detected by metabolomics sequencing.The primary objective is to explore the serum metabolic markers of acute graft versus host disease,acute kidney injury, and major adverse cardiac events within 100 days after transplantation,the secondary objective is to observe the high-risk factors for early complications.

Conditions

Interventions

TypeNameDescription
OTHERSerum metabolomics sequencingSerum samples from the day before pre-treatment, day after pre-treatment, 2 weeks,4 weeks,8 weeks and 12 weeks after transplantation will be detected by metabolomics sequencing.

Timeline

Start date
2024-05-01
Primary completion
2026-12-31
Completion
2026-12-31
First posted
2024-04-26
Last updated
2024-04-26

Source: ClinicalTrials.gov record NCT06386445. Inclusion in this directory is not an endorsement.